Kim Sablich - 08 Mar 2023 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
EVP, GM of U.S., Commercial Ma
Signature
By: Adam Guttman, as attorney in fact For: Kimbely Sablich
Issuer symbol
JAZZ
Transactions as of
08 Mar 2023
Net transactions value
-$421,043
Form type
4
Filing time
10 Mar 2023, 17:10:38 UTC
Previous filing
07 Mar 2023
Next filing
07 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Sale $244,264 -1,752 -5.2% $139.42 31,821 08 Mar 2023 Direct F1, F2
transaction JAZZ Ordinary Shares Sale $176,780 -1,261 -4% $140.19 30,560 08 Mar 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.95 to $139.94. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3 Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $139.97 to $140.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.